Drug Combination Details
| General Information of the Combination (ID: C96787) | |||||
|---|---|---|---|---|---|
| Name | Betulinic Acid NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Metastatic lymph node neoplasm
[ICD-11: 2D60]
|
Investigative | [1] | ||
|
Esophageal cancer
[ICD-11: 2B70]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | PCNA | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | POU5F1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SOX2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | TE-11 | CVCL_1761 | Esophageal squamous cell carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Betulinic acid enhances the chemical sensitivity of esophageal cancer cells to cisplatin by inhibiting cell proliferation, reducing cell stemness, and inducing pyroptosis. | |||||
